ASX Announcements.
| Date | Price sens. | Headline | pages | |
|---|---|---|---|---|
| 22/01/2021 | ! | Immutep Quarterly Activities Report & Appendix 4C | 10 | |
| 22/01/2021 | ! | Ulcerative Colitis Phase II Study of GSK2831781 Discontinued | 2 | |
| 07/01/2021 | ! | Recruitment of Head & Neck Cancer Patients Completed for Ph2 | 2 | |
| 04/01/2021 | Resignation and Appointment of Joint Company Secretary | 1 | ||
| 04/01/2021 | Change in substantial holding | 10 | ||
| 31/12/2020 | Appendix 2A | 16 | ||
| 31/12/2020 | Change in substantial holding | 6 | ||
| 30/12/2020 | Change in substantial holding | 8 | ||
| 30/12/2020 | ! | Immutep granted US patent for Eftilagimod alpha with a PD-1 | 2 | |
| 29/12/2020 | Change in substantial holding | 8 | ||
| 24/12/2020 | Change of Director's Interest Notice - Dr Howard | 3 | ||
| 24/12/2020 | Appendix 2A | 16 | ||
| 24/12/2020 | Becoming a substantial holder | 9 | ||
| 18/12/2020 | Change in substantial holding | 6 | ||
| 17/12/2020 | Change in substantial holding | 6 | ||
| 16/12/2020 | ! | Immutep Upscales Efti Manufacturing | 2 | |
| 16/12/2020 | Change in substantial holding | 6 | ||
| 15/12/2020 | ! | Operational Update | 2 | |
| 15/12/2020 | Ceasing to be a substantial holder | 1 | ||
| 15/12/2020 | Change in substantial holding | 6 | ||
| 11/12/2020 | Appendix 2A | 16 | ||
| 10/12/2020 | ! | Immutep's partner EOC Pharma to start Ph II trial in MBC | 2 | |
| 10/12/2020 | ! | Overall Survival Data from Ph IIb AIPAC Breast Cancer trial | 4 | |
| 27/11/2020 | Change in substantial holding | 6 | ||
| 25/11/2020 | Cleansing Notice | 1 | ||
| 24/11/2020 | Change of substantial holding from AEF | 4 | ||
| 24/11/2020 | Appendix 2A | 16 | ||
| 19/11/2020 | ! | Proposed issue of Securities - IMM | 5 | |
| 19/11/2020 | Immutep Investor Presentation | 52 | ||
| 19/11/2020 | ! | Immutep completes a A$29.6 million placement | 3 | |
| 19/11/2020 | ! | Immutep expands TACTI-002 Collaboration Trial with MSD | 3 | |
| 18/11/2020 | Change in substantial holding | 6 | ||
| 17/11/2020 | ! | Trading Halt | 2 | |
| 17/11/2020 | ! | Pause in Trading | 1 | |
| 10/11/2020 | ! | Encouraging Phase II TACTI-002 Data Reported at SITC 2020 | 5 | |
| 09/11/2020 | ! | Immutep Announces Australian Patent Grant for IMP701 | 2 | |
| 06/11/2020 | Change of Director's Interest Note - Grant Chamberlain | 3 | ||
| 06/11/2020 | Appendix 3G | 15 | ||
| 06/11/2020 | Proposed issue of Securities - IMM | 5 | ||
| 03/11/2020 | Immutep to present TACTI-002 phase 2 data at SITC 2020 | 2 | ||
| 02/11/2020 | Lapse of Unlisted Options | 1 | ||
| 30/10/2020 | ! | Immutep enters into a Licence & Collaboration with LabCorp | 2 | |
| 27/10/2020 | Results of Meeting | 2 | ||
| 27/10/2020 | Immutep AGM 2020 - Chairman's Address | 3 | ||
| 27/10/2020 | ! | Immutep AGM 2020 - CEO Marc Voigt's Presentation | 21 | |
| 23/10/2020 | ! | COVID-19 phase 2 investigator initiated trial commences | 4 | |
| 22/10/2020 | ! | Immutep Quarterly Activities Report & Appendix 4C | 9 | |
| 21/10/2020 | ! | Immutep granted European patent for IMP761 | 2 | |
| 19/10/2020 | Immutep to present AIPAC Overall Survival data at SABCS 2020 | 2 | ||
| 06/10/2020 | Change in substantial holding | 6 | ||
| 05/10/2020 | Appendix 3Y - Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
| 05/10/2020 | Appendix 3Y - Change of Director's Interest Notice - Mr Meyers | 3 | ||
| 05/10/2020 | Appendix 3Y - Change of Director's Interest Notice - Mr Voigt | 3 | ||
| 02/10/2020 | Appendix 2A | 17 | ||
| 02/10/2020 | Appendix 3G | 15 | ||
| 28/09/2020 | Annual Report filed on Form 20-F with SEC | 137 | ||
| 25/09/2020 | Notice of Annual General Meeting/Proxy Form | 28 | ||
| 25/09/2020 | Appendix 4G & Corporate Governance Statement | 35 | ||
| 25/09/2020 | Annual Report to shareholders | 87 | ||
| 18/09/2020 | ! | Immutep reports improving results from INSIGHT-004 trial | 3 | |
| 18/09/2020 | ! | Improving results from stage 1 of TACTI-002 Ph II trial | 4 | |
| 14/09/2020 | Change in substantial holding | 6 | ||
| 11/09/2020 | 2020 Annual General Meeting and Key Dates | 2 | ||
| 31/08/2020 | ! | IMM and Monash Uni receive funding grant for LAG-3 Research | 2 | |
| 26/08/2020 | New data to be presented at ESMO for eftilagimod alpha | 3 | ||
| 25/08/2020 | ! | Appendix 4E & 2020 Full Year Statutory Accounts | 85 | |
| 18/08/2020 | ! | Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study | 2 | |
| 17/08/2020 | Immutep Investor Update | 14 | ||
| 11/08/2020 | ! | Immutep Granted US Patent for Eftilagimod Alpha | 2 | |
| 11/08/2020 | Lapse of Unlisted Options | 1 | ||
| 27/07/2020 | Change in substantial holding | 6 | ||
| 23/07/2020 | ! | Immutep Quarterly Activities Report & Appendix 4C | 9 | |
| 21/07/2020 | Change in substantial holding | 6 | ||
| 15/07/2020 | ! | Immutep Announces United States Patent Grant for IMP701 Antibody | 2 | |
| 29/06/2020 | ! | Immutep Completes Recruitment for Part A of TACTI-002 trial | 3 | |
| 22/06/2020 | ! | Immutep receives A$1,437,826 R&D Tax Incentive | 2 | |
| 01/06/2020 | ! | Immutep announces improving data from TACT I - 002 ph II trial | 4 | |
| 01/06/2020 | ! | Immutep Reports First Result from INSIGHT - 004 Study | 3 | |
| 29/05/2020 | ! | Immutep Receives $3.6M R&D French Tax Incentive | 2 | |
| 27/05/2020 | Immutep webcast to present new data from 2020 ASCO meeting | 2 | ||
| 07/05/2020 | Becoming a substantial holder from AEF | 4 | ||
| 07/05/2020 | ! | Immutep Granted Japanese Patent for Eftilagimod Alpha | 2 | |
| 07/05/2020 | Change in substantial holding | 6 | ||
| 05/05/2020 | Cleansing Notice | 1 | ||
| 04/05/2020 | Appendix 2A | 16 | ||
| 01/05/2020 | Immutep presents at NWR Virtual Small Cap Health Conference | 1 | ||
| 30/04/2020 | ! | INSIGHT-004 and TACTI-002 data to be presented at ASCO | 2 | |
| 29/04/2020 | ! | Proposed issue of Securities - IMM | 5 | |
| 29/04/2020 | Immutep Investor Presentation | 51 | ||
| 29/04/2020 | ! | Immutep completes A$12 million placement | 3 | |
| 28/04/2020 | ! | Immutep Reports Positive Phase II TACTI-002 Data | 5 | |
| 27/04/2020 | ! | Trading Halt | 2 | |
| 22/04/2020 | Enrollment completed for the INSIGHT-004 Study | 3 | ||
| 20/04/2020 | ! | Immutep March Quarterly Activities Report & Appendix 4C | 10 | |
| 16/04/2020 | ! |
Immutep advances its LAG-3 agonist for autoimmune diseases
|
2 | |
| 14/04/2020 | ! |
Immutep presents TACTI-002 data at AACR Virtual Meeting
|
2 | |
| 08/04/2020 | ! |
EOC Pharma confirms plans to advance Efti in China for MBC
|
2 | |
| 26/03/2020 | ! | 20 | ||
| 25/03/2020 | ! | 4 | ||
| 20/03/2020 | 3 | |||
| 16/03/2020 |
Change of Director's Interest Notice - Mr Chamberlain
|
2 | ||
| 09/03/2020 | Immutep receives 2nd IND approval for efti from US FDA | 2 | ||
| 02/03/2020 | Change in substantial holding | 6 | ||
| 25/02/2020 | Immutep Clinical Update & Results Global Webcast Slides | 23 | ||
| 21/02/2020 | Change in substantial holding | 6 | ||
| 21/02/2020 | ! | Half Yearly Report and Accounts | 30 | |
| 19/02/2020 | ! | Immutep reports positive TACTI-002 data | 5 | |
| 05/02/2020 | Change in substantial holding | 6 | ||
| 04/02/2020 | Immutep to present TACTI-002 data at German Cancer Congress | 2 | ||
| 29/01/2020 | ! | Immutep Activities Report | 4 | |
| 29/01/2020 | ! | Appendix 4C - Quarterly | 5 | |
| 10/01/2020 | Immutep Corporate Presentation | 33 | ||
| 09/01/2020 | ! | Immutep expands Part C of TACTI-002 due to positive data | 2 | |
| 06/01/2020 | Change in substantial holding | 6 | ||
| 02/01/2020 | Change of Director's Interest Notice | 3 | ||
| 02/01/2020 | Appendix 3B | 15 | ||
| 19/12/2019 | ! | INSIGHT-004 clinical trial update | 3 | |
| 09/12/2019 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
| 09/12/2019 | Change of Director's Interest Notice - Dr Howard | 2 | ||
| 09/12/2019 | Change of Director's Interest Notice - Mr Voigt | 3 | ||
| 02/12/2019 | Appendix 3B | 16 | ||
| 22/11/2019 | Immutep Investor Update | 13 | ||
| 14/11/2019 | ! | Immutep announces European patent grant for LAG525 antibody | 2 | |
| 08/11/2019 | ! | IMM presents positive interim phase 2 TACTI-002 data at SITC | 3 | |
| 01/11/2019 | Update - Consolidation Split - IMM | 4 | ||
| 01/11/2019 | 2019 AGM CEO Presentation | 24 | ||
| 01/11/2019 | 2019 AGM Chairman's Address | 3 | ||
| 01/11/2019 | Results of Annual General Meeting | 2 | ||
| 31/10/2019 | Consolidation/Split - IMM | 4 | ||
| 28/10/2019 | ! | Operational Update | 3 | |
| 24/10/2019 | Change in substantial holding | 6 | ||
| 23/10/2019 | ! | Appendix 4C - quarterly | 5 | |
| 15/10/2019 | ! | Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma |
23 | |
| 10/10/2019 | ! | Immutep receives A$2.5M R&D French Tax Incentive | 2 | |
| 10/10/2019 | Immutep to present data at upcoming Industry Conferences | 2 | ||
| 04/10/2019 | Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
| 04/10/2019 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
| 03/10/2019 | Appendix 3B | 15 | ||
| 30/09/2019 | Immutep Investor Presentation | 39 | ||
| 30/09/2019 | Notice of Annual General Meeting/Proxy Form | 31 | ||
| 30/09/2019 | Annual Report to shareholders | 82 | ||
| 30/09/2019 | Appendix 4G & Corporate Governance Statement | 32 | ||
| 26/09/2019 | ! | Immutep expands Part A of TACTI-002 due to positive data | 3 | |
| 24/09/2019 | Annual Report filed on Form 20-F with SEC | 199 | ||
| 23/09/2019 | ! | Immutep to receive GBP4M Milestone Payment from GSK | 2 | |
| 17/09/2019 | ! | Japanese patent granted for LAG525 antibody | 2 | |
| 22/08/2019 | ! | Immutep granted European patent for IMP321 in cancer | 2 | |
| 20/08/2019 | ! | Appendix 4E & 2019 Full Year Statutory Accounts | 83 | |
| 13/08/2019 | Ceasing to be a substantial holder from AEF | 3 | ||
| 09/08/2019 | Change in substantial holding | 5 | ||
| 07/08/2019 | Change of Director's Interest Notice - Mr Chamberlain | 2 | ||
| 07/08/2019 | Change of Director's Interest Notice - Mr Voigt | 2 | ||
| 06/08/2019 | Immutep completes fully underwritten A$6M Entitlement Offer | 2 | ||
| 01/08/2019 | ! | Entitlement Offer Results & Shortfall Notification | 2 | |
| 26/07/2019 | ! | Operational Update | 4 | |
| 26/07/2019 | ! | Appendix 4C - quarterly | 5 | |
| 19/07/2019 | Becoming a substantial holder from AEF | 3 | ||
| 19/07/2019 | Change in substantial holding | 6 | ||
| 17/07/2019 | Mailing of Offer Booklet for Entitlement Offer | 1 | ||
| 17/07/2019 | Cleansing Notice | 1 | ||
| 17/07/2019 |
Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
|
1 | ||
| 09/07/2019 |
Cleansing Notice
|
1 | ||
| 09/07/2019 |
Letter to Ineligible Shareholders
|
2 | ||
| 09/07/2019 |
Letter to Eligible Shareholders
|
3 | ||
| 09/07/2019 |
Appendix 3B
|
14 | ||
| 09/07/2019 | ! |
Immutep Entitlement Offer Booklet
|
56 | |
| 09/07/2019 | ! |
Immutep Capital Raising Presentation
|
27 | |
| 09/07/2019 | ! |
Immutep raises A$10M via placement & entitlement offer
|
4 | |
| 05/07/2019 | ! | 2 | ||
| 25/06/2019 | ! |
Immutep completes recruitment of AIPAC trial in MBC
|
3 | |
| 25/06/2019 |
Immutep hosts Key Opinion Leader Call
|
2 | ||
| 21/06/2019 | ! |
Immutep granted Australian patent for eftilagimod alpha
|
2 | |
| 13/06/2019 | ! | 2 | ||
| 06/06/2019 | ! | 3 | ||
| 03/06/2019 | 14 | |||
| 03/06/2019 |
Immutep Poster Presentation at ASCO
|
3 | ||
| 23/05/2019 | ! | 2 | ||
| 17/05/2019 | ! | 2 | ||
| 10/05/2019 | 2 | |||
| 08/05/2019 | 67 | |||
| 30/04/2019 | ! | 4 | ||
| 24/04/2019 | ! | 5 | ||
| 02/04/2019 | 29 | |||
| 27/03/2019 | 2 | |||
| 26/03/2019 | 10 | |||
| 25/03/2019 | 13 | |||
| 22/03/2019 | ! | 2 | ||
| 19/03/2019 | 2 | |||
| 08/03/2019 | ! | 2 | ||
| 07/03/2019 | ! | 1 | ||
| 06/03/2019 | ! | 4 | ||
| 06/03/2019 | ! | 3 | ||
| 04/03/2019 | 2 | |||
| 27/02/2019 | 29 | |||
| 26/02/2019 | 2 | |||
| 25/02/2019 | 18 | |||
| 31/01/2019 | 14 | |||
| 24/01/2019 | ! |
Appendix 4C - quarterly
|
5 | |
| 07/01/2019 | ! | 3 | ||
| 04/01/2019 | 3 | |||
| 04/01/2019 | 4 | |||
| 02/01/2019 |
Appendix 3B
|
15 | ||
| 24/12/2018 | Becoming a substantial holder | 4 | ||
| 21/12/2018 | Disclosure Under LR 3.10.5A and 7.1A.4(b) | 2 | ||
| 21/12/2018 | Cleansing Notice | 1 | ||
| 21/12/2018 | Appendix 3B | 14 | ||
| 20/12/2018 | ! | Cleansing prospectus for issue of warrants | 46 | |
| 19/12/2018 | ! | Immutep announces US$5.2 million capital raising | 3 | |
| 29/11/2018 | ! | European patent granted for IMP321 & antibody combinations | 2 | |
| 28/11/2018 | ! | Immutep granted European patent for IMP321 | 2 | |
| 27/11/2018 | ! | Immutep presents new TACTI-mel data at ICI Europe Summit | 3 | |
| 26/11/2018 | Change of Director's Interest Notice - Dr Howard | 2 | ||
| 21/11/2018 | Appendix 3B | 14 | ||
| 16/11/2018 | Results of Meeting | 3 | ||
| 16/11/2018 | 2018 AGM CEO Presentation | 23 | ||
| 16/11/2018 | 2018 AGM Chairman's Address | 3 | ||
| 12/11/2018 | ! | Positive interim TACTI-mel data presented at SITC | 3 | |
| 01/11/2018 | ! | Operational Update | 4 | |
| 30/10/2018 | AusBiotech Invest presentation slides | 11 | ||
| 25/10/2018 | ! | Appendix 4C - quarterly | 5 | |
| 22/10/2018 | Annual Report filed on Form 20-F with SEC | 127 | ||
| 11/10/2018 | Notice of Annual General Meeting/Proxy Form | 27 | ||
| 11/10/2018 | Annual Report to shareholders | 80 | ||
| 11/10/2018 | Appendix 4G & Corporate Governance Statement | 32 | ||
| 04/10/2018 | Appendix 3B & cleansing notice | 15 | ||
| 02/10/2018 | Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
| 02/10/2018 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
| 02/10/2018 | Appendix 3B & cleansing notice | 15 | ||
| 02/10/2018 | Ceasing to be a substantial holder from AEF | 3 | ||
| 02/10/2018 | Immutep to present at SITC 2018 | 2 | ||
| 28/09/2018 | Appendix 3B & cleansing notice | 14 | ||
| 27/09/2018 | Appendix 3B & cleansing notice | 14 | ||
| 27/09/2018 | Change in substantial holding from AEF | 3 | ||
| 26/09/2018 | Immutep to present at Ladenburg Thalmann conference | 1 | ||
| 24/09/2018 | ! | Immutep enters into collaboration with Pfizer & Merck KGaA | 4 | |
| 07/09/2018 | Immutep presentation for BioCentury NewsMakers conference | 29 | ||
| 03/09/2018 | Change in substantial holding from AEF | 3 | ||
| 03/09/2018 | ! | Progress towards clinical development of IMP761 | 2 | |
| 21/08/2018 | ! | Appendix 4E & 2018 Full Year Statutory Accounts | 82 | |
| 21/08/2018 | ! | Immutep receives A$1.9M from French R&D tax cash rebate | 2 | |
| 16/08/2018 | Immutep to present at BioCentury NewsMakers conference | 2 | ||
| 07/08/2018 | ! | Immutep secures Canadian patent grant for IMP731 antibody | 2 | |
| 07/08/2018 | ! | TACTI-mel Patient Recruitment Complete & Operational Update | 3 | |
| 31/07/2018 | ! | Immutep receives IND approval from US FDA for IMP321 | 2 | |
| 30/07/2018 | ! | Appendix 4C - quarterly | 5 | |
| 02/07/2018 | ! | Immutep submits IND application with FDA | 2 | |
| 19/06/2018 | Investor Update | 13 | ||
| 19/06/2018 | ! | Mid-point of patient enrolment reached in AIPAC trial | 2 | |
| 04/06/2018 | Immutep Poster Presentations at ASCO | 2 | ||
| 30/05/2018 | ! | Webcast slides for TACTI-mel clinical trial data | 25 | |
| 30/05/2018 | ! | New Data from Ongoing TACTI-mel Study | 2 | |
| 25/05/2018 | 3rd Annual Advances in Immuno-Oncology Congress Presentation | 37 | ||
| 17/05/2018 | Webcast to discuss interim results from TACTI-mel | 3 | ||
| 15/05/2018 | Response to ASX Price Query | 3 | ||
| 04/05/2018 | Immutep to present at ASCO | 2 | ||
| 23/04/2018 | Appendix 4C | 5 | ||
| 13/04/2018 | Appendix 3B | 13 | ||
| 13/04/2018 | Completion of Share Purchase Plan | 2 | ||
| 03/04/2018 | ! | Operational Update | 2 |
SEC Filing.
| Date | Filing | Description | Link |
|---|---|---|---|
| 2021-01-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-21-004405 (34 Act) Size: 37 KB |
|
| 2020-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-330035 (34 Act) Size: 31 KB |
|
| 2020-12-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-319222 (34 Act) Size: 27 KB |
|
| 2020-12-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-318256 (34 Act) Size: 36 KB |
|
| 2020-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-315082 (34 Act) Size: 61 KB |
|
| 2020-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-315081 (34 Act) Size: 35 KB |
|
| 2020-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-298335 (34 Act) Size: 44 KB |
|
| 2020-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-298314 (34 Act) Size: 35 KB |
|
| 2020-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-290406 (34 Act) Size: 85 KB |
|
| 2020-11-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-289277 (34 Act) Size: 33 KB |
|
| 2020-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-284866 (34 Act) Size: 35 KB |
|
| 2020-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-284100 (34 Act) Size: 51 KB |
|
| 2020-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-278782 (34 Act) Size: 6 MB |
PDF-1, PDF-2, PDF-3 |
| 2020-10-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-276274 (34 Act) Size: 40 KB |
|
| 2020-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-274624 (34 Act) Size: 144 KB |
|
| 2020-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-273969 (34 Act) Size: 30 KB |
|
| 2020-10-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-264945 (34 Act) Size: 193 KB |
|
| 2020-09-25 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Acc-no: 0001193125-20-253940 (34 Act) Size: 11 MB |
|
| 2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-249813 (34 Act) Size: 83 KB |
PDF-1, PDF-2 |
| 2020-09-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-236488 (34 Act) Size: 41 KB |
|
| 2020-08-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-231834 (34 Act) Size: 1 MB |
|
| 2020-08-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-222878 (34 Act) Size: 40 KB |
|
| 2020-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-216609 (34 Act) Size: 44 KB |
|
| 2020-07-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-197957 (34 Act) Size: 139 KB |
|
| 2020-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-193511 (34 Act) Size: 28 KB |
|
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-182966 (34 Act) Size: 39 KB |
|
| 2020-06-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-175807 (34 Act) Size: 23 KB |
|
| 2020-06-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-157640 (34 Act) Size: 72 KB |
PDF-1, PDF-2 |
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-155983 (34 Act) Size: 31 KB |
|
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-153368 (34 Act) Size: 34 KB |
|
| 2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-136644 (34 Act) Size: 28 KB |
|
| 2020-05-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-129395 (34 Act) Size: 37 KB |
|
| 2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-127496 (34 Act) Size: 22 MB |
PDF-1, PDF-2 |
| 2020-04-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-123665 (34 Act) Size: 64 KB |
|
| 2020-04-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-115224 (34 Act) Size: 42 KB |
|
| 2020-04-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-112652 (34 Act) Size: 169 KB |
|
| 2020-04-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-109597 (34 Act) Size: 35 KB |
|
| 2020-04-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-107327 (34 Act) Size: 34 KB |
|
| 2020-04-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-100811 (34 Act) Size: 36 KB |
|
| 2020-03-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-089032 (34 Act) Size: 35 KB |
|
| 2020-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-087787 (34 Act) Size: 38 KB |
|
| 2020-03-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-080961 (34 Act) Size: 39 KB |
|
| 2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-075165 (34 Act) Size: 30 KB |
|
| 2020-03-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-067431 (34 Act) Size: 41 KB |
|
| 2020-02-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-046319 (34 Act) Size: 552 KB |
|
| 2020-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-043738 (34 Act) Size: 61 KB |
|
| 2020-02-14 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals Acc-no: 0001387131-20-001777 (34 Act) Size: 94 KB |
|
| 2020-02-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-024386 (34 Act) Size: 31 KB |
|
| 2020-01-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-018706 (34 Act) Size: 140 KB |
PDF-1, PDF-2 |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-006041 (34 Act) Size: 27 KB |
|
| 2020-01-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16]Acc-no: 0001193125-20-004200 (34 Act) Size: 36 KB | |
| 2020-01-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-001860 (34 Act) Size: 191 KB |
PDF-1, PDF-2 |
| 2019-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-319328 (34 Act) Size: 32 KB |
|
| 2019-12-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-309656 (34 Act) Size: 77 KB |
PDF-1, PDF-2, PDF-3 |
| 2019-12-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-305691 (34 Act) Size: 178 KB |
|
| 2019-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-292512 (34 Act) Size: 23 KB |
|
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-289148 (34 Act) Size: 40 KB |
|
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-282711 (34 Act) Size: 8 MB |
PDF-1, PDF-2. PDF-3. PDF-4 |
| 2019-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-276527 (34 Act) Size: 50 KB |
|
| 2019-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-272123 (34 Act) Size: 107 KB |
|
| 2019-10-15 | F-3 | Registration statement by foreign private issuers Acc-no: 0001193125-19-267683 (33 Act) Size: 359 KB |
|
| 2019-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-267232 (34 Act) Size: 38 KB |
|
| 2019-10-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-264613 (34 Act) Size: 52 KB |
PDF-1, PDF-2 |
| 2019-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-261937 (34 Act) Size: 171 KB |
|
| 2019-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-259428 (34 Act) Size: 13 MB |
PDF-1, PDF-2, PDF-3, PDF-4 |
| 2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-255307 (34 Act) Size: 35 KB |
|
| 2019-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-252416 (34 Act) Size: 23 KB |
|
| 2019-09-23 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Acc-no: 0001193125-19-252176 (34 Act) Size: 13 MB |
|
| 2019-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-247127 (34 Act) Size: 28 KB |
|
| 2019-08-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-226331 (34 Act) Size: 30 KB |
|
| 2019-08-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-225441 (34 Act) Size: 1 MB |
|
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-220211 (34 Act) Size: 10 MB |
|
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-220204 (34 Act) Size: 52 KB |
PDF-2 |
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-220204 (34 Act) Size: 52 KB |
PDF-1 |
| 2019-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-214347 (34 Act) Size: 26 KB |
|
| 2019-07-30 | D | Notice of Exempt Offering of Securities, item 06b Acc-no: 0001209191-19-043598 (33 Act) Size: 8 KB |
|
| 2019-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-206095 (34 Act) Size: 113 KB |
|
| 2019-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-189823 (34 Act) Size: 68 KB |
|
| 2019-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-181460 (34 Act) Size: 31 KB |
|
| 2019-06-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-178045 (34 Act) Size: 32 KB |
|
| 2019-06-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-171778 (34 Act) Size: 26 KB |
|
| 2019-06-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-165320 (34 Act) Size: 27 KB |
|
| 2019-06-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-165318 (34 Act) Size: 162 KB |
|
| 2019-05-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-154569 (34 Act) Size: 22 KB |
|
| 2019-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-150736 (34 Act) Size: 25 KB |
|
| 2019-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-144945 (34 Act) Size: 36 KB |
|
| 2019-05-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-130751 (34 Act) Size: 39 KB |
|
| 2019-04-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-120345 (34 Act) Size: 102 KB |
|
| 2019-04-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-095885 (34 Act) Size: 11 MB |
|
| 2019-03-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-089166 (34 Act) Size: 30 KB |
|
| 2019-03-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-085849 (34 Act) Size: 4 MB |
|
| 2019-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-079827 (34 Act) Size: 31 KB |
|
| 2019-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-070282 (34 Act) Size: 33 KB |
|
| 2019-03-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-065913 (34 Act) Size: 45 KB |
|
| 2019-03-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-065883 (34 Act) Size: 39 KB |
|
| 2019-03-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-062670 (34 Act) Size: 46 KB |
|
| 2019-02-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-055085 (34 Act) Size: 486 KB |
|
| 2019-02-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-052155 (34 Act) Size: 27 KB |
|
| 2019-02-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-050316 (34 Act) Size: 5 MB |
|
| 2019-02-14 | 424B3 | Prospectus [Rule 424(b)(3)] Acc-no: 0001193125-19-038345 (33 Act) Size: 337 KB |
|
| 2019-02-12 | EFFECT | Notice of Effectiveness Acc-no: 9999999995-19-000221 (33 Act) Size: 1 KB |
|
| 2019-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-027147 (34 Act) Size: 2 MB |
|
| 2019-01-14 | F-3 | Registration statement by foreign private issuers Acc-no: 0001193125-19-008155 (33 Act) Size: 380 KB |
|
| 2019-01-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-004095 (34 Act) Size: 41 KB |
|
| 2019-01-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-000902 (34 Act) Size: 146 KB |
|
| 2018-12-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-356488 (34 Act) Size: 305 KB |
|
| 2018-12-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-356410 (34 Act) Size: 168 KB |
PDF-1, PDF-2, PDF-3 |
| 2018-12-21 | D | Notice of Exempt Offering of Securities, item 06b Acc-no: 0001209191-18-063797 (33 Act) Size: 10 KB |
|
| 2018-12-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-352838 (34 Act) Size: 27 KB |
|
| 2018-12-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-352630 (34 Act) Size: 490 KB |
PDF-1, PDF-2, PDF-3, PDF-4 |
| 2018-12-19 | 424B5 | Prospectus [Rule 424(b)(5)] Acc-no: 0001193125-18-352623 (33 Act) Size: 488 KB |
|
| 2018-11-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-335585 (34 Act) Size: 32 KB |
|
| 2018-11-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-335435 (34 Act) Size: 36 KB |
|
| 2018-11-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-334115 (34 Act) Size: 27 KB |
|
| 2018-11-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-332532 (34 Act) Size: 193 KB | |
| 2018-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-329689 (34 Act) Size: 39 KB |
|
| 2018-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-329687 (34 Act) Size: 8 MB |
PDF-2 |
| 2018-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-329687 (34 Act) Size: 8 MB |
PDF-1 |
| 2018-11-16 | CT ORDER | Confidential treatment order Acc-no: 9999999997-18-009006 (34 Act) Size: 105 KB | |
| 2018-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-324662 (34 Act) Size: 38 KB |
|
| 2018-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-319727 (34 Act) Size: 33 KB |
|
| 2018-10-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-312572 (34 Act) Size: 4 MB |
|
| 2018-10-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-308011 (34 Act) Size: 102 KB |
|
| 2018-10-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-306696 (34 Act) Size: 34 KB |
|
| 2018-10-19 | 20-F | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-30249 |
|
| 2018-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-300562 (34 Act) Size: 888 KB |
|
| 2018-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-300478 (34 Act) Size: 15 MB |
|
| 2018-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-300442 (34 Act) Size: 247 KB |
|
| 2018-10-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-293981 (34 Act) Size: 127 KB |
|
| 2018-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-292668 (34 Act) Size: 184 KB |
PDF-1, PDF-2, PDF-3 |
| 2018-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-292527 (34 Act) Size: 119 KB |
|
| 2018-10-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-291188 (34 Act) Size: 23 KB |
|
| 2018-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-288121 (34 Act) Size: 118 KB |
|
| 2018-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-285992 (34 Act) Size: 114 KB |
PDF-2 |
| 2018-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-285992 (34 Act) Size: 114 KB |
PDF-1 |
| 2018-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-285955 (34 Act) Size: 28 KB |
|
| 2018-09-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-269333 (34 Act) Size: 2 MB |
|
| 2018-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-266455 (34 Act) Size: 34 KB |
|
| 2018-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-256678 (34 Act) Size: 1 MB |
PDF-2 |
| 2018-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-256678 (34 Act) Size: 1 MB |
PDF-1 |
| 2018-08-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-251021 (34 Act) Size: 21 KB |
|
| 2018-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-241616 (34 Act) Size: 56 KB |
PDF-2 |
| 2018-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-241616 (34 Act) Size: 56 KB |
PDF-1 |
| 2018-08-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-233634 (34 Act) Size: 24 KB |
|
| 2018-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-232248 (34 Act) Size: 108 KB |
|
| 2018-07-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-211709 (34 Act) Size: 35 KB |
|
| 2018-06-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-197123 (34 Act) Size: 3 MB |
PDF-1 PDF-2 |
| 2018-06-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-183678 (34 Act) Size: 34 KB |
|
| 2018-05-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-179361 (34 Act) Size: 10 MB |
PDF-1 PDF-2 |
| 2018-05-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-177481 (34 Act) Size: 9 MB |
|
| 2018-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-166845 (34 Act) Size: 33 KB |
|
| 2018-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-153820 (34 Act) Size: 32 KB |
|
| 2018-04-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-131968 (34 Act) Size: 117 KB |
|
| 2018-04-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-117066 (34 Act) Size: 21 KB |
|
| 2018-04-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-117059 (34 Act) Size: 115 KB |
|
| 2018-04-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-106513 (34 Act) Size: 29 KB |
Financial Information.
- Annual Report 2020
- Appendix 4E & 2020 Full Year Statutory Accounts
- Half-Year-Report - ended 31 December 2019
- Annual Report 2019
- Appendix 4E & 2019 Full Year Statutory Accounts
- Half-Year-Report - ended 31 December 2018
- Annual Report 2018
- Half-Year-Report - ended 31 December 2017
- Annual Report 2017
- Appendix 4E & 2017 Full Year Statutory Accounts
- Half-Year-Report - ended 31 December 2016
- Annual Report 2016
- Appendix 4E & 2016 Full Year Statutory Accounts
- Half-Year-Report - ended 31 December 2015
- Annual Report 2015
- Half-Year-Report - ended 31 December 2014
- Annual Report 2014
- Half-Year-Report - ended 31 December 2013
- Annual Report 2013
- Half-Year-Report - ended 31 December 2012
- Annual Report 2012
- Annual Report 2011